Streetbeat News

Products Services

UBER

White Castle has partnered with Uber Direct to offer delivery services through its own app. The service will be available in all of White Castle's restaurant markets, allowing customers to pay the same price for their meal as if they were visiting the restaurant, with a flat delivery fee of $4.99. The partnership with Uber Direct makes the app the best value for White Castle delivery.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:48 am

AVGO

GOOG

MRVL

MSFT

Google plans to replace Broadcom with Marvell as its supplier of artificial intelligence chips by 2027. This decision follows a pricing dispute with Broadcom. Google's increased investment in generative AI, triggered by Microsoft-backed OpenAI's launch of ChatGPT, is also noteworthy. Broadcom's stock fell by 6.51%, while Marvell's rose by 3.87%.

Portfolio Pulse from Anusuya Lahiri

September 21, 2023 | 11:42 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) shares could extend losses due to a rise in risk aversion toward growth stocks and company-specific news. Higher bond yields make investment in high-growth tech stocks unattractive. Tesla's production at the Giga Texas factory may remain suspended until September due to factory upgrades. The company is also facing depletion in the Model 3 inventory. Future Fund’s Gary Black expects Tesla’s third-quarter deliveries to undershoot expectations.

Portfolio Pulse from Shanthi Rexaline

September 21, 2023 | 11:35 am

ICE

Intercontinental Exchange (ICE) is set to launch CORSIA Carbon Credit Futures Market, a platform designed to manage emissions exposure from airlines. This move is in line with global efforts to reduce carbon emissions and promote sustainable practices in the aviation industry.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:35 am

TVTX

Travere Therapeutics has announced confirmatory data from the Phase 3 PROTECT study of FILSPARI, demonstrating long-term kidney function preservation in IgA Nephropathy. Although the drug narrowly missed the eGFR total slope endpoint versus active control, Irbesartan, it achieved a clinically meaningful difference. The company plans to meet with regulators and expects to submit a supplemental New Drug Application (sNDA) in 1H 2024 for full approval in the U.S.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:34 am

FLHLF

JAGX

Filament Health Corp. and Jaguar Health, Inc. have successfully completed an import of coca leaf to Filament's Metro Vancouver research and development facility. The import was authorized by the Peruvian Health Authority and acquired from the Empresa Nacional de la Coca. The imported leaves will be used for initial research purposes to look at neuropsychiatric indications.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:33 am

ALGS

Aligos Therapeutics has announced that it has received Investigational New Drug (IND) clearance for its Nonalcoholic Steatohepatitis (NASH) lead, ALG-055009. This clearance will allow the company to proceed with clinical trials.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:32 am

CYBN

Cybin Inc. (NYSE:CYBN) has completed enrollment in its Phase 2 study of CYB003, a treatment for major depressive disorder. The company has reported no serious adverse events and a favorable safety profile. Cybin plans to scale the CYB003 program to a potential Phase 3 study in early 2024. The program is supported by a recently granted U.S. patent and the company anticipates potential Breakthrough Therapy designation, subject to FDA approval, in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:32 am

SNSE

Sensei Biotherapeutics presented new preclinical data at the Seventh Cri-enci-aacr International Cancer Immunotherapy Conference, reinforcing the pharmacokinetic profile, safety characteristics, and mechanism of action of SNS-101. The data from a multi-dose GLP toxicology study in cynomolgus monkeys supports the exceptional PK and safety profile of SNS-101. Mechanistic mouse data shows SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:30 am

BTCUSD

A video from the Crypto ’98 conference featuring Bitcoin pioneer Hal Finney discussing zero-knowledge proofs has resurfaced. Zero-knowledge proofs are cryptographic protocols that allow a user to validate a claim's authenticity without revealing any specifics of the claim. The crypto sector is currently exploring optimal methods for applying ZK-proofs, mainly to expand the Ethereum network's scope. Finney, who was the first recipient of Bitcoin, made significant contributions to privacy-centric technology.

Portfolio Pulse from Benzinga Neuro

September 21, 2023 | 11:29 am